The Weekly Checkup · August 11, 2026

The Weekly Checkup: Week of August 3-7, 2026

The Pulse

I tracked 49 announced transactions this week, with 5 platform deals, 28 services and 21 technology. Quieter on volume than the last two weeks, but not on size: KKR agreed to take Integer Holdings private at $5.7 billion, Supernus and Indivior announced an all-stock CNS merger of equals, and BWXT sold its medical isotope business to Nordic Capital a week after Curium and Lantheus, so the radiopharmaceutical supply chain is consolidating fast.

Quick note on the Advantage write-up from last week, hearing it’s business is mostly out-of-network, which explains the reportedly low multiple.

Listings run from a disaster mental health responder with an 84% margin to an ABA organization asking 0.28x revenue.

🤝 Announced Deals

KKR takes Integer Holdings private

Deal value: $5.7 billion | EV / Revenue: 3.09x | EV / EBITDA: 14.56x

KKR agreed to acquire Integer Holdings, one of the largest medical device CDMOs in the world, for $127 per share in cash, an enterprise value of approximately $5.7 billion. That's a 51.8% premium to the close on April 29, the day before Integer announced a strategic review, and 28.8% to the 30-day VWAP. LTM revenue was $1.84 billion with adjusted EBITDA of $391.5 million, a 21.2% margin. Five banks are arranging the debt.

My take: Only 4.8% of the 52% premium was from deal day; the rest accumulated between April and August, because announcing a "strategic review" after activist pressure (Irenic Capital took board seats in March) is announcing an auction, and the market priced the outcome months before the outcome occurred.

On the price: we have 44 medical device OEM and CDMO transactions going back to 2014, 32 with derivable EBITDA multiples. The median is 12.5x, and the middle half is between 10.1x and 15.3x, so 14.6x is above median but well inside the range, in line with what Paragon fetched from AMETEK and Spectrum Plastics from DuPont. A full price, not a record.

Two things in the comp set surprised me. There's no evidence of a size premium in this category: deals above $500 million clear at the same median as deals below it, which is the opposite of what I found for surgical hospitals last week. And margin doesn't seem to drive the multiple either. What sits at the top of the set is proprietary process: nitinol and smart materials at 17.2x, regulatory consulting at 19.3x, specialty coatings and biomedical textiles at 5x to 8x revenue. What sits at the bottom is commodity fabrication. In outsourced manufacturing, buyers pay for capabilities that are hard to requalify away from, and everything else is a cost-plus business, but in healthcare.

Which is exactly the playbook Integer ran, and you can see how it happened inside our own database. Greatbatch bought Lake Region at 11.9x in 2015 to create Integer. In 2019 Integer sold its lower-margin Advanced Surgical and Orthopedics business to Viant at 1.5x revenue. Then from 2021 through this January it added five capability tuck-ins, Oscor, the Aran and Proxy biomedical textile businesses at 7.7x revenue, Pulse at 12.9x EBITDA, and two coating companies. Prune the commodity work at 1.5x and buy growing proprietary capabilities at 3x to 4x revenue.

BWXT sells its medical business to Nordic Capital

Deal value: up to $800 million | EV / Revenue: 6.15x | EV / EBITDA: ~40x

BWX Technologies agreed to sell BWXT Medical and the Kinectrics stable isotopes business to Nordic Capital for up to $800 million. Per the earnings call, the divested businesses should account for roughly $130 million of 2026 revenue at a margin modestly above the Commercial Operations segment average of 12%, which is where the roughly 40x figure comes from. BWXT keeps a meaningful minority stake and will continue supplying isotope and radiochemical expertise. BWXT acquired Kinectrics outright in January 2025 for $525 million.

My take: This is the second straight week with a radiopharmaceutical supply deal, after Curium's $7 billion move on Lantheus: in nuclear medicine the scarce asset is production and logistics capacity. What's different here is that nobody is paying 40x for $19 million of current EBITDA. The price is for capacity that mostly doesn't generate revenue yet, therapeutic isotopes like actinium-225 and the lutetium-177 supply chain, where demand from approved and pipeline radioligand therapies is running ahead of what the world can produce. This is an infrastructure bet priced off future scarcity, and the "up to" in the headline means a chunk of the $800 million is contingent.

Hinge Health acquires Cylinder Health

Deal value: $105 million cash

Hinge Health agreed to acquire Cylinder Health, a virtual-first digestive health company formerly known as Vivante Health, for $105 million in cash. Cylinder brings nearly 100 enterprise clients covering about two million lives, contracts with two of the three largest PBMs, and, per the earnings call, should contribute $7 to $8 million of 2026 revenue. Hinge reported Q2 revenue of $212.8 million, up 53%, with $99.6 million of quarterly free cash flow, and plans a single integrated app for MSK, pelvic, migraine and GI care in 2027.

My take: Depending on timing, $7 to $8m in 2026 contribution implies a multiple of 3x to 4x, but this deal probably isn't a revenue purchase. Hinge is buying a clinical capability and about 100 enterprise logos it can cross-sell into, and paying for it with roughly one quarter of free cash flow. At the logo level it's about $1 million per enterprise client.

Employers and health plans are exhausted by point solutions, and the survivors of digital health are responding by buying each other until the point solutions become platforms. Included Health bought Firefly last week; Hinge added GI this week; the pitch in both cases is fewer vendors, one app, one contract. For anyone holding a single-condition digital health asset, the message is uncomfortable but far from tragic: your buyer universe is narrowing to the platform consolidators, they're buying capabilities rather than revenue, and they'll price you on what you plug into, not on what you built. Sell into that reality early or plan to be sub-scale in a market that stopped writing standalone contracts.

iRhythm acquires VitalConnect

Deal value: $287.5 million ($237.5 million cash, $50 million stock), plus up to $30 million of interim working capital financing | EV / Revenue: 4.4x

iRhythm agreed to acquire VitalConnect, a San Jose wearable biosensor company whose FDA-cleared platform spans ambulatory cardiac monitoring and multi-vitals hospital monitoring, for approximately $287.5 million, funded from cash on hand plus stock. iRhythm will also provide VitalConnect up to $30 million of working capital financing between signing and close. Founded in 2011, VitalConnect raised capital across ten rounds over fifteen years, including a $39 million round in 2022, a strategic investment from HCA's venture arm, a Series F in 2023, and a $100 million equity-and-debt financing led by Ally Bridge with Trinity Capital debt as recently as February 2025.

My take: Start with the smallest number in the release, the $30 million of interim working capital financing. Acquirers don't lend targets money to survive until closing when the target has options. That line tells you VitalConnect needed this deal to happen on this timeline.

Then the price against the capital. The funding databases disagree on the total, somewhere between roughly $240 million and $385 million depending on whether you count the debt, but every version of the number is uncomfortably close to $287.5 million, and the company raised $100 million just eighteen months ago. Fifteen years, ten rounds, an FDA-cleared platform deployed in hospitals, and an exit at or around total capital in. After repaying the Trinity debt and a preference stack built across a decade of rounds runs its waterfall, my guess is the later preferred does fine and everyone else is sad.

For iRhythm it's a clean trade: one quarter's revenue, paid mostly in cash it already had, for a second FDA-cleared platform, an entry into inpatient and hospital-to-home monitoring where its Zio chest patch doesn’t compete, and an HCA relationship that came in through the investor door.

Fresenius sells two dialysis centers into a nephrologist joint venture

Per two change-of-ownership exemption filings with the Illinois Health Facilities and Services Review Board, Fresenius Medical Care Chicagoland, LLC, an existing joint venture owned 51% by a Fresenius affiliate and 49% by AIN Ventures, LLC, an affiliate of Associates in Nephrology, will acquire two wholly-owned Fresenius dialysis centers: the 20-station Highland Park facility for $3.15m and the 14-station Mundelein facility for $2.75m. The filings state that the fair market value of the assets equals the purchase price in each case. Revenue and EBITDA figures above are from the Medicare cost reports.

My take: We’ve tracked 50 dialysis transactions with public financial details going back to 2010. The 29 controlling deals with derivable EBITDA multiples cleared at a median of 8.2x, while the five deals where physicians bought minority or JV interests cleared at a median of 3.6x. This week's two land at 2.2x and 3.0, or roughly a quarter to a third of what a controlling buyer pays for the same earnings stream.

Some of the gap is discounts (lack of control and marketability). A 49% interest in a single center carries no control and no liquidity, and appraisers apply discounts for both. But discounts alone probably don’t explain it in this case.

Here's why that gap gets attention beyond valuation circles. The physicians buying into these centers are, in the ordinary course, the nephrologists whose patients dialyze there. Under the Anti-Kickback Statute, if an interest is sold to a referral source below fair market value, the discount itself can be treated as remuneration; this isn't a theoretical concern in dialysis. In 2014, DaVita paid $350 million to resolve a False Claims Act suit brought by David Barbetta, a former analyst in its M&A group, plus a $39 million forfeiture tied to two specific joint ventures. The government alleged that DaVita identified physician practices with large renal patient populations and structured JV buy-ins priced to be lucrative for the physicians, selling below fair market value and buying above it. DaVita settled without any admission of wrongdoing, entered a five-year corporate integrity agreement, and unwound eleven joint ventures covering 26 clinics.

To be clear about this week's filings: they state the price is fair market value, Fresenius has its own compliance infrastructure, and a low multiple on cost-report EBITDA is not evidence of anything by itself. Cost-report earnings aren't the adjusted figure an appraiser would use, and the normalizations on a facility like this (management fees, etc.) can move the denominator meaningfully. Sometimes overhead expenses get left off the cost reports entirely. On these transactions, the FMV opinion isn't just a compliance formality that follows the deal. The distance between 8x and 2x has to be accounted for, normalization by normalization, discount by discount, and everyone involved should want that work to be airtight.

I tracked 43 additional transactions this week. Ares is leading a $2.2 billion private credit package financing MedImpact's acquisition of Puerto Rico's Medical Card System, Tarsus agreed to acquire Alkeus and its Stargardt disease program, and New Mountain plans to merge SmarterDx into Datavant on the back of a $2.5 billion recap. Shore Capital's Community Care Partners sold Texas MedClinic to HCA, Sage Dental took nine Tampa Bay practices in one deal, and ClaimsBridge acquired DialysisPPO, a specialty network for pricing dialysis claims. The complete list, with the financial detail Scope is known for, will be available to clients.

🏷️ Active Listings: Businesses You Can Actually Buy

Five listings, five niches, and the margins run from 6% to 84%. Same exercise as always: figure out what the earnings line is actually measuring before arguing about the multiple.

1. Crisis Stabilization and Community Resilience Services, Florida

The company provides rapid-response crisis stabilization and mental health support during disasters and emergencies, deploying multidisciplinary teams of clinicians and crisis specialists to help communities and frontline responders recover.

My take: An 83.6% margin on a clinical services business is not a clinical services margin. A company that "deploys multidisciplinary teams" during disasters almost certainly holds no meaningful fixed clinical payroll. The model is a bench of credentialed 1099 clinicians activated per event, billed to government contracts, FEMA-funded state programs, or corporate EAP arrangements. Between events, costs approach zero. So the 83.6% isn't operational excellence, it's the absence of a cost structure, and the flip side is that the revenue arrives in lumps you don't control. Nobody schedules a hurricane.

That's why this prices at 1.97x cash flow while everything else in behavioral health clears multiples of that. The market is telling you it doesn't believe $2.79 million recurs. Before you decide whether it's wrong, get revenue by contract and by event for five years. If one state contract or one declared disaster produced most of a peak year, you're buying a rolodex and a set of contract vehicles, and those price differently than earnings. The contract vehicles might be the whole asset, honestly. Standing capacity agreements with state emergency management agencies take years to win, and a buyer who already delivers staffing or behavioral services could bolt them on and treat any activation revenue as upside. I'd also ask who personally holds the agency relationships, because in disaster response the principal's phone number is frequently the company.

2. Multi-Location Injury Care Practice, Ohio

Established multi-location practice specializing in accident-related injury care, including auto, work and personal injury, supported by advanced medical equipment and described as having strong demand from legal and insurance referral sources.

My take: "Legal and insurance referral sources" is the key phrase. A practice built on auto and personal injury treats many patients under letters of protection or on liens, meaning the practice gets paid when the underlying case settles. That model can be very profitable, but it changes what every number on this page means. Revenue recognition depends on how the practice books LOP receivables against what actually collects at settlement, and realization on personal injury AR can run anywhere from 30% to 70% of billed charges depending on the attorney relationships and the case mix. So the first diligence item isn't the P&L, it's the AR aging by payer class with three years of realization history, and whether the $4.3 million is cash-basis collections or accrual-basis optimism.

Two Ohio specifics. Workers' comp there is a monopolistic state fund, so the work-injury book runs through Ohio BWC certified provider billing at administered rates. That revenue is more predictable than the PI book but also completely rate-controlled. And the referral relationships themselves deserve a hard look: a practice whose volume depends on a handful of plaintiff firms has concentration risk that behaves exactly like customer concentration, except the customers are law firms and the relationships rarely transfer with the assets. At 6.7x on a 33.6% margin, someone's assuming both the margin and the referrals survive a sale. I'd want the top five referring firms' share of volume before agreeing, and I'd structure a healthy piece of the price contingent on collections from the acquired AR.

3. High-Volume Home Care Agency, Western Pennsylvania

High-volume agency with reimbursement-based revenue, absentee operations, established MCO contracts, high compliance, and what the listing describes as an upcoming rate increase providing significant upside.

My take: Regular readers know the drill on Pennsylvania home care by now, and this listing checks in on the right side of most of it. A 13.3% margin at $22.7 million of revenue is inside the plausible band for Medicaid-heavy personal care, the absentee claim is credible at this scale because a $23 million agency runs on managers whether the owner shows up or not, and 7.6x on $3 million of earnings prices it like the platform entry it would be for a buyer seeking Western Pennsylvania exposure.

Two things to press on. First, "established MCO contracts" is the asset, and Pennsylvania's Community HealthChoices procurement is still unsettled after the courts ordered the rebid, which means every agency whose value is its contracts carries some version of the network risk I wrote about in Issue #17. Get written confirmation of assignability and ask each MCO directly about network status post-close. Second, "upcoming rate increase provides significant upside" cuts both ways and sellers only ever mention one direction. A business whose margin expansion depends on a state rate action is a business whose margin compression can arrive the same way. Underwrite the current rates, treat the increase as free option value, and if the broker insists the increase belongs in the price, ask why the seller is exiting right before it lands. You’ll probably get an interesting answer.

4. Multi-Location Therapy and ABA Organization

Multi-location therapy and applied behavior analysis organization, $17 million of 2024 revenue growing to $19.5 million in 2025. Clinic-based services are the primary revenue driver, with school-based at roughly 20% of ABA revenue and in-home at 10%. Therapy is billed through private insurance and Medicaid; about 30% of ABA revenue is Medicaid. Some real estate comes with the sale.

My take: Put this against our behavioral health comp set and the reset in autism services is right there in one listing. Autism and IDD transactions in our database have a median EBITDA multiple around 11x, set mostly in the years when payers were expanding coverage and platforms were paying for growth. This is $19.5 million of growing revenue offered at $5.5 million, real estate included. 0.28x revenue.

What happened in between is the margin. A 6.2% EBITDA margin is the ABA staffing crisis expressed as arithmetic: RBT wages up, turnover brutal, supervision ratios binding, and Medicaid rates in most states not moving nearly enough to cover it. The listing even says management "made some key investments to assist recruiting," which is a candid way of saying labor is the problem. So the buyer question isn't whether 4.6x is cheap. It's whether this is a 6% margin business having a hard couple of years or a 6% margin business permanently, because at 6% you're one rate cut or one bad quarter of utilization from zero. The payer detail worth chasing: 30% Medicaid ABA means 70% commercial, which is a better mix than most, and the school-system revenue is a third payer type with its own contracting cycle. If the commercial book is concentrated in one or two plans, this is fragile. If it's spread, a disciplined operator who fixes scheduling density and supervisor leverage could maybe plausibly get to 12% and double the earnings without adding a client.

5. Exclusive-Territory Medical Device Distribution, Onondaga County, New York

Established healthcare supply business with long-term client relationships, recurring revenue, and strong cash flow in a specialized niche, marketed as an exclusive-territory medical device distribution business.

My take: A 62.5% margin means this isn't distribution in any inventory-carrying sense. Distributors who buy, warehouse and resell product run gross margins of 20% to 35% and EBITDA margins in the single digits to low teens. A business keeping 62 cents of every revenue dollar is functionally a commissioned sales agency: the manufacturer ships and bills, and this company gets paid for owning the relationships in a defined territory. Which means the entire enterprise value lives inside one document, the distribution or rep agreement, and the questions that matter are all in its boilerplate. Is the exclusivity contractual or customary? What's the term, and what triggers termination? And the one that decides whether this deal exists: what happens on a change of control? Manufacturer agreements routinely require consent to assignment, and a manufacturer facing a $9.5 million transfer of its territory has every incentive to renegotiate the economics or take the territory direct. If the agreement terminates on sale, the buyer paid 6.1x for a piece of paper that just expired.

The 6.1x itself is priced like the agreement is permanent, and at 3.8x revenue it's the richest revenue multiple I've put in this section all year. For the right buyer, an adjacent rep organization that already carries complementary lines and can get the manufacturer's blessing pre-signing, this could work. For anyone else, the sequencing is the deal: manufacturer consent first, in writing, with a fresh multi-year term, before a dollar moves. And ask who the relationships belong to. In a territory rep business with margins like this, there's usually one person the surgeons actually call, and you should know whether that person is staying.

Sign-Off

Thanks for the read, and let me know what you think!

- Will

The Weekly Checkup is published every Tuesday morning. Written for general informational purposes. Access to Scope Research healthcare M&A databases or valuation consulting engagements through HealthFMV require a separate agreement.

Get the next one in your inbox

Subscribe free